NCT04760522 · ClinicalTrials.gov record · last posted 2023-11-29
Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program
Study acronym: GE-MED
StatusRecruiting
PhaseNot applicable
Started2021-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 29, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES).
The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented.
The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.
Amendment record
4 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 4 times since 2021-02-16; most recent amendment 2023-11-28. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2021-06-10
Status change Not Yet Recruiting→Recruitingv2
| NCT Number |
NCT04760522 |
| Lead Sponsor |
University Hospital Tuebingen
|
| Conditions |
Rare Diseases, Genetic Predisposition to Disease |
| Enrollment |
12,000 participants |
| Start Date |
2021-06-01 |
| Primary Completion |
2026-07 (estimated) |
| Study Completion |
2027-07 (estimated) |
| Updated on ClinicalTrials.gov |
2023-11-29 |